Thein H. Oo, MD, FRCPE, FACP
Department of Pulmonary Medicine, Division of Internal Medicine
About Dr. Oo
Thein H Oo received his medical degree from the Institute of Medicine II, Rangoon, Burma. He completed internal medicine training at hospitals recognized by the Royal Colleges of Physicians of the United Kingdom and at Albany Medical College, Albany, New York. He underwent Clinical Oncology training at Christie Hospital, Manchester, UK, and Hematology-Medical Oncology Clinical and Research Fellowship at St Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, USA. During his fellowship training, he received extensive training in clinical hematology and oncology, apheresis medicine, some aspects of laboratory hematology and transfusion medicine. In his final year of fellowship training, he trained as a research fellow in the world-renowned Erythrocyte Membrane Research Laboratory at the St Elizabeth's Medical Center and also served as an Administrative Chief Fellow.
Read More
After completing the fellowship training, he joined the faculty of Tufts University School of Medicine, Boston. He was recruited to the Section of Thrombosis & Benign Hematology at The University of Texas MD Anderson Cancer Center in July 2010. His interests include supportive care in cancer, hemostasis and thrombosis, bone marrow failure syndromes, consultative hematology and the graduate medical education. He participates in local, national and international educational and hematology practice activities. He has published over one hundred and seventy manuscripts, book chapters and abstracts. He previously served as a committee memeber on the Test Material Development Committee and Committee on Practice, both of American Society of Hematology, on the Membership and Communications Committee of the International Society on Thrombosis and Haemostasis and on the Faculty Senate. He currently serves as a reviewer for many journals and and as a committee member on Venous Thromboembolism Network of the United States (VENUS). He is a Fellow of the Royal College of Physicians and a Fellow of the American College of Physicians.
Present Title & Affiliation
Primary Appointment
Professor, Department of Pulmonary Medicine, Section of Benign Hematology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor of Medicine, Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Research Interests
1. Supportive Care in Cancer
2. Hemostasis and Thrombosis
3. Bone Marrow Failure Syndromes
Education & Training
Degree-Granting Education
| 1991 | Institute of Medicine II, Rangoon, MM, Medicine, MBBS in Medicine |
Postgraduate Training
| 1999-2002 | Clinical Fellowship, Hematology & Medical Oncology Subspecialty, Tufts University School of Medicine (St Elizabeth's Medical Center), Boston, Massachusetts |
| 1997-1999 | Clinical Residency, Internal Medicine, Albany Medical Center, Albany, New York |
| 1996-1997 | Clinical Residency, Clinical Oncology, Christie Hospital & Paterson Institute for Cancer Research, Manchester |
| 1995-1996 | Clinical Residency, Internal Medicine, North Middlesex University Hospital, London |
| 1994-1995 | Clinical Residency, Internal Medicine, Royal Albert Edward Infirmary, Wigan |
| 1994-1994 | Clinical Residency, Internal Medicine, Halton General Hospital, Runcorn |
| 1993-1994 | Elective Rotation, Old Age Psychiatry, Queen Elizabeth Psychiatric Hospital, Birmingham |
| 1992-1993 | Self-study, PLAB and USMLE examinations, Mandalay, Rangoon (Myanmar), London (UK) |
Board Certifications
| 2023 | Basic Life Support |
| 2003 | American Board of Internal Medicine - Hematology |
| 2002 | American Board of Internal Medicine - Medical Oncology |
| 1999 | American Board of Internal Medicine - Internal Medicine |
Experience & Service
Academic Appointments
Associate Professor, Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2016
Associate Professor, Department of Medicine, Tufts University School of Medicine, Boston, MA, 2009 - 2010
Assistant Professor, Department of Medicine, Tufts University School of Medicine, Boston, MA, 2002 - 2009
Clinical Associate, Department of Internal Medicine, Tufts University School of Medicine, Boston, MA, 2001 - 2002
Administrative Appointments/Responsibilities
Chief Fellow, St Elizabeth's Medical Center, Boston, MA, 2001 - 2002
Other Appointments/Responsibilities
Senator, Faculty Senate, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2018
Consultant to Pharmacy Services, Anticoagulation Task Force, University of Texas M.D. Anderson Cancer, Houston, TX, 2015 - Present
Interview Panel for Resident Selection, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2016
Advisory Board Member, International Advisory Board, Royal College of Physicians of Edinburgh, Edinburgh, 2014 - 2016
Chair, Continuing Quality Improvement, St Elizabeth's Medical Center, Boston, MA, 2007 - 2010
Officer, Physicians-in-transition Division, Burmese Medical Association of North America, Baltimore, MD, 2007 - Present
Consultant, Hematology, Good Samaritan Medical Center, Brockton, MA, 2006 - 2010
Consultant, Hematology, Kindred Hospital, Boston, MA, 2005 - 2009
Consultant, Hematology, Norwood Hospital, Norwood, MA, 2005 - 2010
Coordinator, Advance Newsletter, Department of Medicine, St Elizabeth's Medical Center, Boston, MA, 2004 - 2010
Coordinator, Hematology/Oncology Grand Rounds, St Elizabeth's Medical Center, Boston, Massachusetts, 2004 - 2010
Faculty Interview Panel for Interns Selection, St Elizabeth's Medical Center, Boston, MA, 2003 - 2010
Institutional Committee Activities
Question Item writer, Question Item Writing Task Force (Hematology), 2023 - Present
Member, Credentials Committee of the Medical Staff, 2022 - Present
Member, Immunotherapy Toxicity Working Group, 2020 - Present
Member, Cancer Associated Thrombosis and Device-Related Thrombosis, 2016 - Present
Member, Media Team, 2014 - 2015
Member, Membership and Communications Committee, 2012 - 2018
Member, Quality Council, Division of Internal Medicine, 2011 - 2014
Member, Grand Rounds Planning Committee, Division of Internal Medicine, University of Texas M. D. Anderson Cancer Center, 2011 - Present
Member, American Hospital Formulary Service, 2008 - 2009
Member, Committee on Practice, 2007 - 2010
Member, Conflict of Interest Compliance Officer, 2007 - 2010
Member, Test Material Development Committee, 2006 - 2008
Member, Consultant to Pharmacy Service, 2005 - 2010
Member, Curriculum Committee, Tufts University School of Medicine, 2003 - 2005
Honors & Awards
| 2017 | Certificate of Appreciation, ASEAN Federation of Endocrine Societies |
| 2017 | Certificate of Honor, Myanmar Society of Hematology |
| 2015 | 5-year Service Award, The University of Texas M.D. Anderson Cancer Center |
| 2013 | Certificate of Honor, Myanmar Medical Association - Myanmar Society of Hematology |
| 2011 | 2011 Teaching Team of the Year, Hematology/Oncology Fellowship Program, Division of Cancer Medicine, UT M. D. Anderson Cancer Center |
| 2010 | Certificate of Appreciation, American Society of Hematology |
| 2008 | Certificate of Appreciation, Myanmar American Medical Education Society |
| 2007 | Service Award, St Elizabeth's Medical Center of Boston |
| 2005 | Stohlman Library Distinguished Author Award, St Elizabeth's Medical Center of Boston |
| 2002 | All Star Award, St Elizabeth's Medical Center of Boston, |
| 1996 | Membership, Royal College of Physicians of the United Kingdom (MRCP [UK]) |
| 1990 | Distinctions (Honors) in Surgery, Obstetrics & Gynecology, Child Health, Institute of Medicine II, Rangoon |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Htut TW, Thein KZ, Oo TH. Hyperhomocystinemia associated thrombosis in patients with pernicious anemia. J Community Hosp Intern Med Perspect 15(1):22-29, 2025. e-Pub 2025. PMID: 39867151.
- Wilson NR, Lockhart JR, Garcia-Perdomo HA, Oo TH, Rojas-Hernandez CM. Management and Outcomes of Hematological Immune-related Adverse Events: Systematic Review and Meta-analysis. J Immunother 45(1):13-24, 2022. e-Pub 2022. PMID: 34469413.
- Houghton DE, Billett HH, Gaddh M, Onadeko O, George G, Wang TF, Oo TH, Feng M, Dasgupta M, Jaglal M, Streiff MB, Simpson P, Gali R, Baumann Kreuziger L. Risk for pulmonary emboli after removal of upper extremity central catheters when associated with deep vein thrombosis. Blood Adv 5(14):2807-2812, 2021. e-Pub 2021. PMID: 34264267.
- Baumann Kreuziger L, Gaddh M, Onadeko O, George G, Wang TF, Oo TH, Jaglal M, Houghton DE, Streiff MB, Gali R, Feng M, Simpson P, Billett HH. Treatment of cather-related thrombosis in patients with hematologic malignancies: a Venous thromboEmbolism Network U.S. retrospective cohort study. Thromb Res 202:155-161, 2021. e-Pub 2021. PMID: 33862470.
- Wilson NR, Khan M, Cox T, Nassif M, Qiao W, Garg N, Aung FM, Oo TH, Rojas-Hernandez C. Bleeding outcomes in thrombocytopenic acute leukemic patients with venous thromboembolism. eJournal of Haematology, 2020. e-Pub 2020.
- Agha AM, Gill C, Balanescu DV, Donisan T, Palaskas N, Lopez-Mattei J, Hassan S, Kim PY, Charitakis K, Cilingiroglu M, Oo TH, Kroll M, Durand JB, Hirsch-Ginsberg C, Marmagkiolis K, Iliescu C. Identifying Hemostatic Thresholds in Cancer Patients Undergoing Coronary Angiography Based on Platelet Count and Thromboelastography. Front Cardiovasc Med 7:9, 2020. e-Pub 2020. PMID: 32118047.
- Leaf RK, Ferreri C, Rangachari D, Mier J, Witteles W, Ansstas G, Anagnostou T, Zubiri L, Piotrowska Z, Oo TH, Iberri D, Yarchoan M, Salama AKS, Johnson DB, Leavitt AD, Rahma OE, Reynolds KL, Leaf DE. Clinical and Laboratory Features of Autoimmune Hemolytic Anemia Associated with Immune Checkpoint Inhibitors. Am J Hematol 94(5):563-574, 2019. e-Pub 2019. PMID: 30790338.
- Khan M, Cox TM, Nassif M, Alzubaidi MA, Garg N, Qiao W, Aung FM, Oo TH, Rojas-Hernandez CM. Comparative outcomes of thrombocytopenic acute leukemic patients with venous thromboembolism at a comprehensive cancer center. J Thromb Thrombolysis 45(3):377-385, 2018. e-Pub 2018. PMID: 29417408.
- Ng AH, Goldman L, Fu JB, Oo TH, Chisholm GB, Liu DD, Bedi A, Bruera E. Frequency of venous thromboembolism events during acute inpatient rehabilitation in a comprehensive cancer centre. J Rehabil Med 49(9):758-764, 2017. e-Pub 2017. PMID: 28929167.
- Wong M, Oo TH, Qiao W, Garg N, Rojas-Hernandez CM. Performance of 4T score and heparin-platelet factor 4 antibody in the diagnosis of heparin-induced thrombocytopenia (HIT) in cancer. J Thromb Thrombolysis 44(2):261-266, 2017. e-Pub 2017. PMID: 28677022.
- Torres HA, Roach LR, Mahale P, Economides MP, Blechacz B, Miller E, Borchardt R, Rashid A, Oo TH, Shukla B, Farida M, Ericsson CD, Granwehr BP, Raad II. Transdisciplinary Approach to Managing Hepatitis C Virus Infection in Patients at a Tertiary Care Cancer Center. J Natl Compr Canc Netw 14(9):1185-8, 2016. e-Pub 2016. PMID: 27587628.
- Parker EP, Siebert R, Oo TH, Schneider D, Hayette S, Wang C. Sequencing of t(2;7) Translocations Reveals a Consistent Breakpoint Linking CDK6 to the IGK@ Locus in Indolent B-Cell Neoplasia. J Mol Diagn 15(1):101-9, 2013. e-Pub 2013. PMID: 23127611.
- Li X, Chen H, Oo TH, Daly TM, Bergman LW, Liu SC, Chishti AH, Oh SS. A co-ligand complex anchors Plasmodium falciparum merozoites to the erythrocyte invasion receptor band 3. J Biol Chem 279(7):5765-71, 2004. e-Pub 2004. PMID: 14630931.
- Hesketh PJ, Nauman CJ, Hesketh AM, LaPointe J, Fogarty K, Oo TH, Lau DH, Edelman MJ, Gandara DR. Unfavorable therapeutic index of cisplatin/gemcitabine/vinorelbine in advanced non-small-cell lung cancer. Clin Lung Cancer 4(1):47-51, 2002. e-Pub 2002. PMID: 14653876.
Invited Articles
- Laguna JC, Cooksley T, Ahn S, Tsoukalas N, Oo TH, Brito-Dellan N, Esposito F, Escalante C, Font C, Study Group MH. Catheter-related thrombosis (CRT) in patients with solid tumors: a narrative review and clinical guidance for daily care. Support Care Cancer 30(10):8577-8588, 2022. e-Pub 2022. PMID: 35932317.
- Htut TW, Thein KZ, Aung KL, Oo TH. Primary ambulatory thromboprophylaxis in patients with pancreatic cancer receiving chemotherapy: hope or hype?. Supportive Care in Cancer 30(10):8511-8517, 2022. e-Pub 2022. PMID: 35579754.
- Font C, Marta de Herreros G, Tsoukalas N, Brito-Dellon N, Espósito F, Escalante C, Oo TH. Thrombotic microangiopathy (TMA) in adult patients with solid tumors: a challenging complication in the era of emerging anticancer therapies (in press). Supportive Care in Cancer 30(10):8599-8609, 2022. e-Pub 2022. PMID: 35545722.
- Oo TH. Nonhematologic manifestations of pernicious anemia. Discov Med 34(173):165-169, 2022. e-Pub 2022. PMID: 36476278.
- Kesselman A, Oo TH, Johnson M, Stecker MS, Kaufman J, Trost D. Current Controversies in Inferior Vena Cava Filter Placement: AJR Expert Panel Narrative Review. AJR Am J Roentgenol 216(3):563-569, 2021. e-Pub 2021. PMID: 33206563.
- Oo TH. Diagnostic difficulties in pernicious anemia. Discov Med 28(155):247-253, 2019. e-Pub 2019. PMID: 32053765.
- Rojas-Hernandez CM, Oo TH. Direct oral anticoagulants in the prevention and treatment of venous thromboembolism in patients with cancer: new insights from randomized controlled trials. Drugs 79(6):621-631, 2019. e-Pub 2019. PMID: 30905033.
- Rojas-Hernandez CM, Oo TH. The unusual nutritional and toxin-related underproduction anemias: Approaching the riddle beyond iron, cobalamin, and folate. Discov Med 25(136):67-74, 2018. e-Pub 2018. PMID: 29579413.
- Oo TH, Rojas-Hernandez CM. Challenging Clinical Presentations of Pernicious Anemia. Discov Med 24(131):107-115, 2017. e-Pub 2017. PMID: 28972879.
- Rojas Hernandez CM, Oo TH. Advances in mechanisms, diagnosis and treatment of pernicious anemia. Discov Med 19(104):159-68, 2015. e-Pub 2015. PMID: 25828519.
- Zalpour A, Oo TH. Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence. Drug Des Devel Ther 2014(8):2181-2191, 2014. e-Pub 2014. PMID: 25395835.
- Oo TH, Hesketh PJ. Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting. Nat Clin Pract Oncol 2(4):196-201, 2005. e-Pub 2005. PMID: 16264934.
Other Articles
- Lin J, Rodriguez-Martinez P, Oo TH, Shuyu E, Jorgensen J, Rojas-Hernandez CM Durvalumab-induced pure white cell aplasia. J Immunother 47(1):7-9, 2024. PMID: 37904601.
- Thein KZ, Htut TW, Myat YM, Han MM, Win MA, Phyu EM, Oo TH Updated meta-analysis of randomized controlled trials on primary outpatient thromboprophylaxis in patients with gastric and gastroesophageal junction cancers receiving chemotherapy. Proc (Bayl Univ Med Cent) 36(5):635-640, 2023. PMID: 37614866.
- Htut TW, Thein KZ, Oo TH Meta-analysis of randomized controlled trials on primary ambulatory thromboprophylaxis in patients with ovarian cancer receiving chemotherapy. Proc (Bayl Univ Med Cent) 35(3):332-336, 2022. PMID: 35518830.
- Htut TW, Thein KZ, Quick DP, Oo TH Meta-analysis of randomized controlled trials on primary ambulatory thrombopeophylaxis in patients with non-pancreatic gastrointestinal cancers receiving chemotherapy. Proc (Bayl Univ Med Cent) 35(1):51-55, 2022. PMID: 34970032.
- Htut TW, Thein KZ, Oo TH Pernicious Anemia: Pathophysiology and diagnostic difficulties. J Evid Based Med 14(2):161, 2021. PMID: 34015185.
- Sandow LP, Cannon LA, Weston NR, Aung KL, Oo TH The Clinical Applicability of Primary Thromboprophylaxis in Ambulatory Patients With Pancreatic Cancer. Pancreas 50(4):494-499, 2021. PMID: 33939659.
- Oo TH Secondary erythrocytosis due to Hemoglobin San Diego. Proc (Bayl Univ Med Cent) 34(1):159-160, 2020. PMID: 33456185.
- Oo TH Commentary: Pernicious anemia can be treated effectively with a single high dose of cobalamin. Practice Update, 2020.
- Thein KZ, Htut TW, Ball S, Swarup S, Sultan A, Oo TH Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Res Treat 183(2):479-487, 2020. PMID: 32647939.
- Thein KZ, Quick DP, Htut TW, Tijani L, Oo TH Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Lung Cancer Receiving Chemotherapy. Lung 198(3):575-579, 2020. PMID: 32189065.
- Shuai W, Wagner CE, Sukswai N, Medeiros LJ, Bueso-Ramos C, Oo TH Gaucher disease type 1 first recognized in an elderly patient with thrombocytopenia and lung adenocarcinoma. Clin Case Rep 7(9):1804-1805, 2019. PMID: 31534758.
- Oo TH Commentary: VTE prophylaxis and treatment in patients with cancer. Practice Update, 2019.
- Oo TH Commentary: Prevention of VTE in ambulatory cancer patients. Practice Update, 2019.
- Oo TH Commentary: Risk of thromboembolic and bleeding outcomes following hematologic cancers. Practice Update, 2019.
- Simkins A, Maiti A, Short NJ, Jain N, Popat U, Patel KP, Oo TH Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation. Hematol Oncol Stem Cell Ther 12(2):115-118, 2019. PMID: 29409729.
- Myint ZW, Oo TH, Thein KZ, Tun AM, Saeed H Copper deficiency anemia: review article. Ann Hematol 97(9):1527-1534, 2018. PMID: 29959467.
- Thein KZ, Yeung SJ, Oo TH Primary thromboprophylaxis (PTP) in ambulatory patients with lung cancer receiving chemotherapy: A systematic review and meta-analysis of randomized controlled trials (RCTs). Asia Pac J Clin Oncol 14(3):210-216, 2018. PMID: 28949077.
- Oo TH My approach to prophylaxis for pelvic surgery. Practice Update, 2018.
- Oo TH, Miranda RN Renal cell carcinoma metastasizing to the myeloproliferative bone marrow. Blood Res 53(1):9, 2018. PMID: 29662856.
- Sun Y, Lee SK, Oo TH, Rojas-Hernandez CM Management of Immune-mediated Cytopenias in the Era of Cancer Immunotherapy: A Report of 4 Cases. J Immunother 41(1):32-34, 2018. PMID: 29111982.
- Tun AM, Thein KZ, Myint ZW, Oo TH Pernicious anemia: Fundamental and practical aspects in diagnosis. Cardiovasc Hematol Agents Med Chem 15(1):17-22, 2017. PMID: 28164751.
- Thein KZ, S-C Y, Oo TH Primary thrombophylaxis (PTP) in ambulatory patients with lung cancer receiving chemotherapy: A systematic review and meta-analysis of randomized controlled trials (RCTs). Asia-Pac J Clin Oncol, 2017.
- Rojas-Hernandez CM, Oo TH, García-Perdomo HA Risk of intracranial hemorrhage associated with therapeutic anticoagulation for venous thromboembolism in cancer patients: a systematic review and meta-analysis. J Thromb Thrombolysis 43(2):233-240, 2017. PMID: 27704333.
- Oo TH, Hu S Copper deficiency related bone marrow changes secondary to long-term total parenteral nutrition. Clin Case Rep 5(2):195-196, 2017. PMID: 28174650.
- Khan M, Paul S, Farooq S, Oo TH, Ramshesh P, Jain N Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6-Phosphate Dehydrogenase Deficiency. Curr Drug Saf 12(1):13-18, 2017. PMID: 28078984.
- Sasaki K, Popat U, Jain P, Kadia T, Patel K, Patel K, Jain N, Takahashi K, Young K, Miranda RN, Oo TH, Lu H, Pemmaraju N Successful treatment of aplastic anemia-paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation. Clin Case Rep 4(8):765-7, 2016. PMID: 27525080.
- Thein KZ, Myint ZW, Tun AM, Oo TH Cancer Associated Thrombosis: Focus on prevention and treatment of venous thromboembolism. Cardiovasc Hematol Agents Med Chem, 2016. PMID: 27188892.
- Tun NM, Guevara E, Oo TH Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy: A systematic review and meta-analysis of randomized controlled trials. Blood Coagul Fibrinolysis 27(3):270-4, 2016. PMID: 26963028.
- Oo TH COUNTER - Ambulatory patients with solid cancers who are high risk for venous thromboembolism should not be treated with thromboprophylaxis. HemOnc Today 16(22):13, 2015.
- Pundole X, Konoplev S, Oo TH, Lu H Autoimmune Myelofibrosis and Systemic Lupus Erythematosus in a middle-aged male presenting only with severe anemia: A case report. Medicine (Baltimore) 94(19):1-4, 2015. PMID: 25984660.
- Zalpour A, Oo TH Update on edoxaban for the prevention and treatment of thromboembolism: Clinical Applications based on current evidence. Adv Hematol 2015:920361, 2015. PMID: 26351456.
- Gay CM, William WN, Wang SA, Oo TH Thymoma Complicated by Acquired Amegakaryocytic Thrombocytopenia and Pure Red Cell Aplasia. J Natl Compr Canc Netw 12(11):1505-9, 2014. PMID: 25361796.
- Salhotra A, Oo TH JAK2(V617F) positive latent myeloproliferative neoplasm presenting with splanchnic vein thrombosis. Indian J Hematol Blood Transfus 30(Suppl 1):4-8, 2014. PMID: 25332520.
- Shah DR, Daver N, Borthakur G, Hirsch-Ginsberg C, Oo TH Pernicious Anemia With Spuriously Normal Vitamin B12 Level Might Be Misdiagnosed As Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 14(4):e141-3, 2014. PMID: 24630920.
- Torres HA, Mahale P, Miller ED, Oo TH, Frenette C, Kaseb AO Coadministration of Telaprevir and Transcatheter Arterial Chemoembolization in Hepatitis C Virus-Associated Hepatocellular Carcinoma. World J Hepatol 5(6):332-5, 2013. PMID: 23805358.
- Tun NM, Oo TH Prevention and Treatment of Venous Thromboembolism with New Oral Anticoagulants: A Practical Guide for Clinicians. Thrombosis 2013:183616, 2013. PMID: 23533745.
- Kumar S, Wong G, Maysky M, Shulman M, Olenchock S, Falzon-Kirby M, Oo TH Amniotic fluid embolism complicated by paradoxical embolism and disseminated intravascular coagulation. Am J Crit Care 19(4):379-82, 2010. PMID: 19435949.
- Arnaoutakis K, Oo TH Bronchus-associated lymphoid tissue lymphomas. South Med J 102(12):1229-33, 2009. PMID: 20016430.
- Oo TH Rituximab can induce a durable response in refractory immune thrombocytopenic purpura associated with chronic lymphocytic leukemia: Case report and review of the Literature. Clinical Leukemia 2(2):140-2, 2008.
- Smeglin A, Ansari M, Skali H, Oo TH, Maysky M Marantic endocarditis and disseminated intravascular coagulation with systemic emboli in presentation of pancreatic cancer. J Clin Oncol 26(8):1383-5, 2008. PMID: 18323562.
- Ambika S, Oo TH Translocation (2;7)(p11.2;q22) in a newly diagnosed low-grade B-cell non-Hodgkin lymphoma. Cancer Genet Cytogenet 181(1):65-6, 2008. PMID: 18262057.
- Oo TH Trisomies 3 and 18 in a newly diagnosed chronic lymphocytic leukemia. Cancer Genet Cytogenet 176(2):175, 2007. PMID: 17656265.
- Oo TH, Kenney L Therapy-related chronic myelomonocytic leukemia with unique chromosomal abnormalities: monosomy 7 and t(12;17)(p13;q11.2). Am J Hematol 82(3):248-9, 2007. PMID: 16924641.
- Mohamed T, Sanjay R, Sycheva T, Aish L, Schneider D, Oo TH Amiodarone-associated bone marrow granulomas: a report of 2 cases and review of the literature. Int J Hematol 85(2):101-4, 2007. PMID: 17321985.
- Oo TH Clopidogrel-associated thrombotic thrombocytopenic purpura presenting with coronary artery thrombosis. Am J Hematol 81(11):890-1, 2006. PMID: 16804940.
- Sinha S, Aish L, Oo TH Morphologic heterogeneity of acute promyelocytic leukemia: therapy-related acute promyelocytic leukemia presenting with FAB-M2 morphology. Am J Hematol 81(6):475-6, 2006. PMID: 16680741.
- Oo TH Rituximab is effective in the treatment of refractory immune thrombocytopenic purpura associated with chronic lymphocytic leukemia. South Med J 98(12):1227-8, 2005. PMID: 16440930.
- Sinha S, Aish L, Oo TH Primary thyroid lymphoma presenting with stridor. Am J Clin Oncol 28(5):531-3, 2005. PMID: 16199998.
- Gaur S, Oo TH, Aish LS, Mansoor S Gastric relapse of solitary bone plasmacytoma. Am J Clin Oncol 28(3):325-6, 2005. PMID: 15923810.
- Oo TH Trisomy 8 in a newly diagnosed chronic lymphocytic leukemia. Cancer Genet Cytogenet 156(1):94-5, 2005. PMID: 15588867.
- Gaur S, Aish LS, Oo TH Difficult diagnostic and therapeutic cases: CASE 3. presentation of prostate cancer with cervical adenopathy. J Clin Oncol 22(5):957-8, 2004. PMID: 14990654.
- Oo TH, Aish LS, Schneider D, Hesketh PJ Uncommon hematologic malignancies. Case 2. Calcification in untreated primary mediastinal large B-cell lymphoma with sclerosis. J Clin Oncol 21(22):4249-51, 2003. PMID: 14615456.
- Oo TH, Aish LS, Schneider D, Hassoun H Carcinoid tumor presenting with bone marrow metastases. J Clin Oncol 21(15):2995-6, 2003. PMID: 12885821.
- Oo TH, Delafuente M, Hassoun H, Oo TR Possible association between hairy cell leukemia and Behçet's disease. South Med J 96(3):323-4, 2003. PMID: 12659376.
- Oo TH, Martin L, Hesketh PJ Adrenal hemorrhage secondary to metastasis from lung cancer. Clin Lung Cancer 4(3):183-5, 2002. PMID: 14706168.
- Oo TH, Aish LS, Hassoun H Unusual presentations of lymphoma: Case 1. Sea-blue histiocytes in non-Hodgkin's lymphoma. J Clin Oncol 20(7):1942-3, 2002. PMID: 11919255.
- Oo TH Spot Diagnosis. Albany Medical Review 2(2):13, 1999.
- Oo T A 35-year-old man with fever and dry cough. Albany Med Review 2(1):4-5, 1999.
Editorials
- Oo TH. The evolving role of open access journals and Clinical & Experimental Pharmacology Journal. Clin Exp Pharmacol J, 2012.
Abstracts
- Thein KZ, Htut TW, Han MM, Myat YM, Win MA, Phyu EM, Oo TH. Systematic review and meta-analysis of randomized controlled trials on primary outpatient thromboprophylaxis in patients with gastric and gastro-esophageal junction cancers. Blood 140 (Supplement 1):7997-7998, 2022. e-Pub 2022.
- Antonucci JV, DeAos I, Oo T, Varticovski L. STI 571 inhibition of BCR/ABL transformed cells, is potentiated by hyperthermia. Blood, 2020. e-Pub 2020.
- Karp-Leaf R, Ferreri C, Reynolds KL, Rangachari D, Mier J, Wesley Witteles W, Ansstas G, Theodora Anagnostou T, Leyre Zubiri L, Piotrowska Z, Oo TH, Iberri D, Yarchoan M, April Salama A, Rahma O, Leaf D. Clinical Features of Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia: A Series of 14 Cases. Blood, 2018. e-Pub 2018.
- Baumann-Kreuziger L, Manila Gaddh M, Onadeko O, Gemlyn George G, T-F W, Oo TH, Ming Feng M, Simpson P, Gali R, Billett HH. Wide Variation in Duration of Anticoagulation after Catheter-Related Thrombosis: A Venous Thromboembolism Network US Multicenter Retrospective Cohort Study. Blood, 2018. e-Pub 2018.
- Thein KZ, Ball S, Zaw MH, Tun AM, Quirch M, Hardwicke F, D'Cunha N, Tijani L, Jones C, Oo TH. Updated meta-analysis of randomized controlled trials (RCTs) to determine the CDK 4/6 inhibitors associated venous thromboembolism (VTE) risk in hormone receptor-positive breast cancer (BC) patients. Ann Oncol 29 Suppl 8:viii606, 2018. e-Pub 2018. PMID: 32137619.
- Thein KZ, Zaw MH, Tun AM, Jones C, Radhi S, Hardwicke F, Oo TH. Incidence of venous thromboembolism in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK 4/6 inhibitors: A systematic review and meta- analysis of randomized controlled trials. Cancer Research, 2017. e-Pub 2017.
- Ko H, Rojas-Hernandez CM, Oo TH. Clinical Outcomes of Acquired Factor VIII Inhibitors in Cancer Population: A Systematic Review. Blood, 2017. e-Pub 2017.
- Oo TH. Thrombosis in Endocrine Disorders. J ASEAN Fed Endo Soc, 2017. e-Pub 2017.
- Oo TH, Rojas-Hernandez CM. When cancer patients are HIT: A literature review of heparin-induced thrombocytopenia (HIT) and clinical outcomes in cancer patients, 2017. e-Pub 2017.
- Thein KZ, Tun AM, Yeung S-C J, Oo TH. Risk of Bleeding from Primary Thromboprophylaxis (PTP) in Patients with SolidCancer Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCT) [Poster Presentation at ASH Meeting]. Blood 128(22):3820, 2016. e-Pub 2016.
- Thein KZ, Yeung S-C J, Oo TH. A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCT) in Ambulatory Thromboprophylaxis (ATP) in Patients with Lung Cancer Receiving Chemotherapy [Poster Presentation at ASH meeting]. Blood 128(22):3825, 2016. e-Pub 2016.
- Khan M, Nassif M, Alzubaidi M, Cox T, Oo TH, Garg N, Rojas-Hernandez CM. Outcomes of Venous Thromboembolism (VTE) Treatment in Thrombocytopenic Leukemic Patients. Blood 128(22):4964, 2016. e-Pub 2016.
- Thein KZ, Tijani L, Oo TH. Low- Molecular Weight Heparins (LMWH) Versus Vitamin K Antagonists (VKAs) in the Treatment and Secondary Prevention of Cancer-Associated Venous Thromboembolism (VTE): A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs). Blood 128(22):1180, 2016. e-Pub 2016.
- Wong M, Oo T, Qiao W, Garg N, Rojas-Hernandez C. Performance of 4T score and HIT Antibody in the Diagnosis of Heparin-Induced Thrombocytopenia in Cancer Patients [Poster Presentation]. Am J Clin Pathol, 2016. e-Pub 2016.
- Thein KZ, Brock PA, Page VD, Oo TH. Primary thromboprophylaxis in Ambulatory patients with lung cancer receiving chemotherapy: A systematic review and meta-analysis of randomized controlled trials [Poster Presentation]. Journal of the National Comprehensive Cancer Network:e-23, 2016. e-Pub 2016.
- Thein KZ, Brock PA, Page V, Oo TH. Ambulatory Thromboprophylaxis (ATP) in patients with lung cancer receiving chemotherapy: A systematic review and meta-analysis of randomized controlled trials [Oral Presentation]. Division of Internal Medicine 2016 Research Retreat Program Syllabus:143, 2016. e-Pub 2016.
- Oo TH. Cancer Associated Thrombosis. 5th Myanmar Haematology Conference Program Book, 2015. e-Pub 2015.
- George M, Arndt Weibel K, Wilson MG, Oo TH, Javle M. Gemcitabine-induced thrombotic microangiopathy-Hemolytic remic syndrome (TMA-HUS) without thrombocytopenia. Division of Internal Medicine 2015 Research Retreat Program Syllabus:78, 2015. e-Pub 2015.
- Pundole X, Konoplev S, Oo TH, Lu H. Autoimmune myelofibrosis and systemic lupus erythematosus in a middle-aged male presenting only with severe anemia. Division of Internal Medicine 2015 Research Retreat Program Syllabus:94, 2015. e-Pub 2015.
- Tun NM, Guevara E, Oo TH. Efficacy of therapeutic dose versus prophylactic dose of anticogulants in the primary prevention of thrombotic events in ambulatroy patients with solid malignancies receiving chemotherapy: A systematic review and meta-analysis of randomized controlled trials. Blood, 2014. e-Pub 2014.
- Tun NM, Guevara E, Oo TH. Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy: A systematic review and meta-analysis of randomized controlled trials. Blood, 2014. e-Pub 2014.
- Kyvernitokis A, Oo TH, Kroll MH, Afshar-Kharghan V, Mahale P, Torres HA. Incidence and management of hematological toxicities associated with treatment of hepatitis C virus infection in cancer patients. Blood, 2014. e-Pub 2014.
- Kroll MH, Pemmaraju N, Oo TH, Afshar-Kharghan V, Kroll S. Mortality from cancer-associated venous thromboembolism. Blood, 2014. e-Pub 2014.
- Oo TH. New anticoagulants in the prevention and treatment of venous thromboembolism. Joint Thai-Myanmar Hematology Conference Program Book:4, 2013. e-Pub 2013.
- Pemmaraju N, Kroll MB, Afshar-Kharghan V, Oo TH. Bleeding risk in thrombocytopenic cancer patients with venous thromboembolism (VTE) receiving anticoagulation. Blood (ASH Annual Meeting Meeting Abstracts) 120, 2012. e-Pub 2012.
- Torres HA, Mahale P, Saxena A, Afshar-Kharghan V, Kroll MH, Th O. Use of growth factors in treatment of hepatitis C viral infection in cancer patients. Blood, 2012. e-Pub 2012.
- Habib M, Khan F, Unterborn J, Oo T. A rare cause of stroke. Fifth Annual Research Poster Symposium of the Massachusetts Medical Society, 2010. e-Pub 2010.
- Wong G, Arnaoutakis A, Oo TH. Retrospective analysis of outcomes of patients with acute leukemia receiving induction chemotherapy at Caritas St Elizabeth's Medical Center from 2002 to 2007. Caritas St Elizabeth's Medical Center Annual Research Day Brochure:26, 2008. e-Pub 2008.
- Wong G, Kumar S, Oo TH. Retrospective analysis of outcome of patients with acute leukemia receiving induction chemotherapy at Caritas St Elizabeth's Medical Center from 2002 to 2006. Caritas St Elizabeth's Medical Center Annual Research Day Brochure:30, 2007. e-Pub 2007.
- Seery TE, Sycheva T, Oo TH. The prevalence of second malignancies and autoimmune diseases in patients with lymphoproliferative disorders. Blood (ASH Annual Meeting Abstracts) 108(11):232b, 2006. e-Pub 2006.
- Mohamed T, Sycheva T, Aish L, Schneider D, Oo TH. Amiodarone-induced bone marrow granulomas. Blood (ASH Annual Meeting Abstracts) 106(11):159b, 2005. e-Pub 2005.
- Oo TH, Gaur S, Tierney J, Ashare A, Weinstein R. Hematocrit-driven referrals for measurement of RBC mass. Is natural history of polycythemia vera changing?. Blood (ASH Annual Meeting Abstracts) 106(11):320-321b, 2005. e-Pub 2005.
- Sinha S, Aish L, Oo TH. Morphologic heterogeneity of acute promyelocytic leukemia (APL). J Clin Oncol 23(16_suppl):6741, 2005. e-Pub 2005.
- Mohamed T, Sycheva T, Aish L, Schneider D, Oo TH. Amiodarone-induced bone marrow granulomas. Caritas St Elizabeth's Medical Center Annual Research Day Brochure:23, 2005. e-Pub 2005.
- Li X, Goel VK, Kariuki M, Yamodo I, Chen H, Oo TH, Daly TM, LeRoy P, Mackesy M, Mahmood A, Gonzalez A, Chishti A, Liu SC, Bergman LW, Oh SS. Erythrocyte invasion of Receptor band-3 in malaria. Caritas St Elizabeth's Medical Center Annual Research Day Brochure:6, 2005. e-Pub 2005.
- Sinha S, Schneider D, Aish L, Oo TH. Morphologic heterogeneity of acute promyelocytic leukemia. Caritas St Elizabeth's Medical Center Annual Research Day Brochure:24, 2005. e-Pub 2005.
- Oo TH, Natarajan N. Rituximab is effective in refractory adult immune thrombocytopenic purpura associated with chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts)(11):74b, 2004. e-Pub 2004.
- Li X, Yamodo IH, Kariuki M, Oo TH, Chishti AH, Oh SS. Both EGF-like modules of Plasmodium falciparum MSP-1 are crucial for interaction with the erythrocyte receptor band-3. Am Soc Trop Med & Hyg 2004 Program and Abstract Book:Abs # 966, 2004. e-Pub 2004.
- Sinha S, Natarajan N, Aish L, Schneider D, Weinstein R, Jameson J, Oo TH. Primary thyroid lymphoma should be considered as a differential diagnosis in patients with a rapidly growing neck mass and stridor. Blood(11):263b, 2003. e-Pub 2003.
- Li X, Chen H, Oo TH, Daly TM, Bergman LW, S-C L, Oh SS, Chishti AH. Plasmodium falciparum invasion of erythrocytes requires direct interaction between parasite ligand ABRA and host band-3 receptor. Blood (ASH Annual Meeting Abstracts)(11):254a, 2003. e-Pub 2003.
- Sinha S, Oo TH, Natarajan N. Polycythemia vera presenting as massive splenic infarct. Blood(11):339b, 2003. e-Pub 2003.
- Li X, Chen H, Oo TH, Bergman LW, Chishti AH, Oh SS. Plasmodium falciparum merozoite surface protein 1 and 9 form a co-ligand complex binding to the erythrocyte receptor band-3. Am Soc Trop Med & Hyg 2003 Program and Abstract Book:201, 2003. e-Pub 2003.
- Antonucci JV, DeAos I, Oo T, Varticovski L. STI 571 inhibition of BCR/ABL transformed cells, is potentiated by hyperthermia. Blood (ASH Annual Meeting Abstracts) 96(11):3461-347a, 2000. e-Pub 2000.
Book Chapters
- Oo TH, Rojas-Hernandez CM. Hematologic Complications of Immune Checkpoint Inhibitors. In: Managing Immunotherapy Related Organ Toxicities: A Practical Guide. Springer, 2022.
- Ng, A, Oo, TH. Hematologic and thromboembolic complications of cancer and their treatment. In: Cancer Rehabilitation: Principles and Practice. Second. DemosMEDICAL, 482-493, 2018.
- Oo TH, Hesketh PJ. Further Improvement in the control of chemotherapy-induced nausea and vomiting: Future Directions. In: Management of Nausea and Vomiting in Cancer and Cancer Treatment. First Ed. Sudbury: Jones & Bartlett, 231-245, 2004.
- Nelson BE, Oo TH, Rojas-Hernandez CM. Autoimmune hemolytic anemia post immune checkpoint inhibitor. In: Challenges Cases in Immunotherapy Related Organ Toxicities (in press). Springer.
- Oo TH, Vega F, Rojas-Hernandez CM. Immune Thrombocytopenic Purpura post immune checkpoint inhibitor therapy. In: Challenges Cases in immunotherapy related organ toxicities (in press). Springer.
- Oo TH, Ng A. Hematologic and thromboembolic complications of cancer and their treatment. In: Cancer Rehabilitation: Principles and Practice. Springer.
Letters to the Editor
- Thein KZ, Oo TH. 2019 international clinical practice guidelines for the treatment of venous thromboembolism. Lancet Oncol 20: e655, 2019.
- Thein KZ, Yeung SJ, Oo TH. Reply to M. Alexander et al. Asia Pac J Clin Oncol 15: 185, 2019.
- Rojas-Hernandez CM, Oo TH, García-Perdomo HA. A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation: comment. J Thromb Haemost 14: 2080-2081, 2016.
- Oo TH. Outpatient thromboprophylaxis with low-molecular-weight heparin in solid tumors: Where do we stand today?. J Thromb Thrombolysis 41: 539-40, 2016.
- Oo TH. Comment on "Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial". J Clin Oncol 34: 515, 2016.
- Cheah CY, Orlowski RZ, Manasanch EE, Oo TH. Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma. Ann Hematol 94: 1605-7, 2015.
- Oo TH. Vitamin B12 deficiency--A 21st century perspective. Clin Med (Lond) 15: 402, 2015.
- Oo TH. Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH: comment. J Thromb Haemost 13: 1351-2, 2015.
- Oo TH. Prevention of VTE in cancer outpatients: guidance from the SSC of the ISTH: comment. J Thromb Haemost 13: 323-4, 2015.
- Oo TH. Presence of paroxysmal nocturnal hemoglobinuria (PNH) clones does not exclude inherited bone marrow failure syndromes (IBMFS). Eur J Haematol 93: 171, 2014.
- Oo TH. Serum ferritin level over 100 ng/ml does not virtually exclude iron deficiency anemia. J R Coll Physicians Edinb 44: 187, 2014.
- Oo TH. Correspondence: Venous thromboembolism in cancer outpatients. J Natl Compr Canc Netw 12: 451-2, 2014.
- Oo TH. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH: a rebuttal. J Thromb Haemost 12: 115-6, 2014.
- Oo TH. Differential diagnoses of macrocytic anemia, reticulocytosis and low serum haptoglobin in patients with myelodysplastic syndromes/acute leukemia: Comment on " Two cases of acute erythroid leukemia presenting with marked macrocytic anemia, reticulocytosis and hemolysis". Intern Med 53: 77, 2014.
- Oo TH. Low-molecular weight heparin prophylaxis should not be recommended even in highly selected solid cancer patients receiving outpatient chemotherapy. J Clin Oncol 31: 4380-1, 2013.
- Oo TH. "Hypofibrinogenemia, dysfibrinogenemia or hypodysfibrinogenemia? : Comment on "The dilemma of inherited dysfibrinogenemia during pregnancy"". Blood Coagul Fibrinolysis 24: 353-4, 2013.
- Oo TH. The Timing of Thrombophilia Testing is Important: Comment on "Left Main Coronary Artery Thrombus Resulting from Combined Protein C and S Deficiency". Intern Med 52: 695, 2013.
- Oo TH. Comments on "Essential Thrombocytosis and Antiphospholipid Antibody Syndrome Causing Chronic Budd-Chiari Syndrome". Indian J Pediatr 79: 1533; author reply 1534, 2012.
- Oo TH. Low molecular weight heparin or semuloparin should not be recommended for thromboprophylaxis in ambulatory solid cancer patients undergoing chemotherapy. Thromb Res 130: 821-2, 2012.
- Oo TH. Inherited cancer syndromes should be considered in young patients with newly diagnosed head and neck cancer. J R Coll Physicians Edinb 41: 187, 2011.
- Oo TH. Comments on "Desvenlafaxine as a possible cause of acquired hemophilia". Gen Hosp Psychiatry 33: e11, 2011.
- Oo TH. Leukocytosis may be seen in patients with undiagnosed myeloproliferative disorders, factitious leukocytosis and venous thromboembolism. Thromb Res 127: 487, 2011.
- Oo TH. Impact of reduced working hours. Many residents under-report their work hours. BMJ 342: d2424, 2011.
- Oo TH. Optimal duration of anticoagulation in idiopathic venous thromboembolism should be determined by multiple variables. J R Coll Physicians Edinb 41: 91-92, 2011.
- Oo TH. Thrombolytic therapy and thrombectomy in phlegmasia cerulea dolens. J R Coll Physicians Edinb 40: 92, 2010.
- Oo TH. Deep vein thrombosis associated with the new oral contraceptive Yasmin. South Med J 102: 985-6, 2009.
- Oo TH. Heparin-induced thrombocytopenia and thrombosis. J Royal Coll Physicians Edinb 39: 286, 2009.
- Oo TH. An American view of the European working time directive and training. BMJ Careers 339, 2009.
- Oo TH. Brain drain and health professionals. Brain drain disseminates skill and advances science. BMJ 325: 219, 2002.
Selected Presentations & Talks
Local Presentations
- 2024. Hematologic complications of immune checkpoint inhibitors. IOTOX Education. Houston, Texas, US.
- 2024. Clinico-pathological conference: A 62-year-old female with 2-year history of thrombocytopenia, splenomegaly, intermittent abdominal pain and intermittent swelling of extremities. Internal Medicine Survivorship Grand Round. Houston, Texas, US.
- 2024. Diagnostic difficulties in vitamin B12 deficiency (Invited). Diagnostic difficulties in vitamin B12 deficiency. Houston, TX, US.
- 2023. Diagnostic difficulties in pernicious anemia (Invited). Diagnostic difficulties in pernicious anemia. Houston, TX, US.
- 2023. Approach to Bleeding Disorders (Invited). Approach to Bleeding Disorders. Houston, TX, US.
- 2022. Hematologic Complications of Immune Checkpoint Inhibitors. IOTOX Clinical Education Symposium. Houston, TX, US.
- 2022. Renal Cell Carcinoma. Renal Cell Carcinoma. Boston, MA, US.
- 2022. Natural History of Heparin-Induced Thrombocytopenia: Lessons from a Retrospective Cancer Patients' Cohort. Natural history of heparin-induced thrombocytopenia: Lessons from a retrospective cancer patients cohort. Houston, TX, US.
- 2022. Clinico-pathologic conference: A 41-year-old man with a history of three cancers in 6 years: A common presentation of a very rare disease. Clinico-pathologic conference: A 41-year-old man with a history of three cancers in 6 years: A common presentation of a very rare disease. Houston, TX, US.
- 2020. Clinico-pathologic conference: A 41-year-old man with a 4-year history of erythrocytosis: A common presentation of an extremely rare disease. Clinico-pathologic conference: A 41-year-old man with a 4-year history of erythrocytosis: A common presentation of an extremely rare disease. Houston, TX, US.
- 2019. Cancer related bleeding, updates on anticoagulation and reversal agents. Cancer related bleeding, updates on anticoagulation and reversal agents. Houston, TX, US.
- 2019. Cancer Associated Thrombosis. Cancer Associated Thrombosis. Houston, TX, US.
- 2018. Direct Oral anticoagulants in primary venous thromboembolism prevention in cancer. Direct Oral anticoagulants in primary venous thromboembolism prevention in cancer, US.
- 2018. Clinico-pathological Conference: A 41-year-old man with anemia: Uncommon presentation of a common disease. Clinico-pathological Conference: A 41-year-old man with anemia: Uncommon presentation of a common disease. Houston, TX, US.
- 2018. New Developments in treating cancer associated venous thromboembolism - Anticoagulation in Ambulatory Patients. New Developments in treating cancer associated venous thromboembolism - Anticoagulation in Ambulatory Patients. Houston, TX, US.
- 2018. New oral anticoagulants and new treatments. New oral anticoagulants and new treatments. Houston, TX, US.
- 2017. Approach to Thrombotic Microangiopathies. Approach to Thrombotic Microangiopathies. Houston, TX, US.
- 2017. Cancer Associated Thrombosis. Cancer Associated Thrombosis. Houston, TX, US.
- 2016. Clinical Significance of Paroxysmal Nocturnal Hemoglobinuria Clones. Clinical Significance of Paroxysmal Nocturnal Hemoglobinuria Clones. Houston, TX, US.
- 2016. Ambulatory Thromboprophylaxis in Patients with Lung Cancer Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [ James S. and Suzanne Cyrus Scholar Award Finalist for Clinical Research Category]. Ambulatory thromboprophylaxis in patients with lung cancer receiving chemotherapy: A systematic review and meta-analysis of randomized controlled trials [ James S. and Suzanne Cyrus Scholar Award Finalist for Clinical Research Category]. Houston, TX, US.
- 2016. Clinicopathologic conference: A 54-Year-Old Man with Anemia: An Unusual Presentation of a Common Disease. Clinicopathologic conference: A 54-Year-Old Man with Anemia: An Unusual Presentation of a Common Disease. Houston, TX, US.
- 2015. Autoimmune Myelofibrosis and Systemic Lupus Erythematosus in a Middle-Aged Male Presenting Only with Severe Anemia. Autoimmune myelofibrosis and systemic lupus erythematosus in a middle-aged male presenting only with severe anemia. Houston, TX, US.
- 2015. Gemcitabine-Induced Thrombotic Microangiopathy-Hemolytic Remic Syndrome (TMA-HUS) without Thrombocytopenia. Gemcitabine-induced thrombotic microangiopathy-Hemolytic remic syndrome (TMA-HUS) without thrombocytopenia. Houston, TX, US.
- 2014. Venous Thromboembolism Prophylaxis in Ambulatory Cancer Patients. Venous Thromboembolism Prophylaxis in Ambulatory Cancer Patients. Houston, TX, US.
- 2013. New Oral Anticoagulants in Clinical Practice. New Oral Anticoagulants in Clinical Practice. Houston, TX, US.
- 2013. Overview of Hemostasis, Fibrinolysis and von Willebrand's Disease. Overview of Hemostasis, Fibrinolysis and von Willebrand's Disease. Houston, TX, US.
- 2011. Approach to Leukocytosis and Leukopenia. Approach to Leukocytosis and Leukopenia. Houston, TX, US.
- 2011. Anemia, Leukopenia and Thrombocytopenia: What do I do next?. Anemia, Leukopenia and Thrombocytopenia: What do I do next?. Houston, TX, US.
- 2011. Cancer-Associated Thrombosis. Cancer-Associated Thrombosis. Houston, TX, US.
- 2011. Approach to Bleeding Disorders and Bleeding Emergencies. Approach to Bleeding Disorders and Bleeding Emergencies. Houston, TX, US.
- 2010. Therapeutic Apheresis. Therapeutic Apheresis. Houston, TX, US.
- 2010. Approach to Bleeding Disorders. Approach to Bleeding Disorders. Houston, TX, US.
- 2010. Hematological Emergencies in Medical Intensive Care Unit. Hematological Emergencies in Medical Intensive Care Unit. Boston, MA, US.
- 2009. Therapeutic Apheresis. Therapeutic Apheresis. Boston, MA, US.
- 2008. Therapeutic Apheresis in Neurological Disorders. Therapeutic Apheresis in Neurological Disorders. Boston, MA, US.
- 2008. Update in Hematology. Update in Hematology. Boston, MA, US.
- 2007. Hematological Emergencies in the Intensive Care Units. Hematological Emergencies in the Intensive Care Units. Boston, MA, US.
- 2007. Update in Hematology. Update in Hematology. Boston, MA, US.
- 2006. Update on Myelodysplastic Syndromes. Update on Myelodysplastic Syndromes. Boston, MA, US.
- 2005. Heparin-induced Thrombocytopenia and Thrombosis. Heparin-induced Thrombocytopenia and Thrombosis. Norwood, MA, US.
- 2005. Neutropenia, MRSA and Necrotic Skin Ulcer. Neutropenia, MRSA and Necrotic Skin Ulcer. Norwood, MA, US.
- 2005. Myelodysplastic Syndromes (Refractory Anemias). Myelodysplastic Syndromes (Refractory Anemias). Norwood, MA, US.
- 2004. Intrathoracic Lymphoma. Intrathoracic Lymphoma. Boston, MA, US.
- 2004. Acute Promyelocytic Leukemia. Acute Promyelocytic Leukemia. Boston, MA, US.
- 2003. Acute Promyelocytic Leukemia - Past, Present and Future. Acute Promyelocytic Leukemia - Past, Present and Future. Boston, MA, US.
Regional Presentations
- 2015. Prevention and Treatment of Venous Thromboembolism in Acute Inpatient Cancer Rehabilitation Units. Prevention and Treatment of Venous Thromboembolism in Acute Inpatient Cancer Rehabilitation Units. Dallas, TX, US.
- 2014. Clinical Approach to Patients with Bleeding Disorders. Association of Physician Assistants in Oncology. Austin, TX, US.
National Presentations
- 2023. Diagnostic difficulties in pernicious anemia. Diagnostic difficulties in pernicious anemia (Webinar). Chicago, IL, US.
- 2022. Updated Meta-Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis in Patients with Advanced Pancreas Cancer Receiving Chemotherapy. Updated meta-analysis of randomized controlled trials on primary outpatient thromboprophylaxis in patients with advanced pancreas cancer receiving chemotherapy. New Orleans, LA, US.
- 2022. Systematic Review and Meta-Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis in Patients with Gastric and Gastro-Esophageal Junction Cancers. Systematic review and meta-analysis of randomized controlled trials on primary outpatient thromboprophylaxis in patients with gastric and gastro-esophageal junction cancers. New Orleans, LA, US.
- 2022. The Natural History of Heparin Induced Thrombocytopenia (HIT) in Cancer Patients. The natural history of heparin induced thrombocytopenia (HIT) in cancer patients. New Orleans, LA, US.
- 2019. A Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Gastrointestinal Cancers Receiving Chemotherapy (poster presentation). A Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Gastrointestinal Cancers Receiving Chemotherapy (poster presentation). Orlando, FL, US.
- 2019. Updated Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Locally Advanced or Metastatic Lung Cancer Receiving Chemotherapy. Updated Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Locally Advanced or Metastatic Lung Cancer Receiving Chemotherapy. Orlando, FL, US.
- 2019. Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Locally Advanced or Metastatic Lung Cancer (LC) Receiving Chemotherapy. Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Locally Advanced or Metastatic Lung Cancer (LC) Receiving Chemotherapy. Orlando, FL, US.
- 2019. Updated Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Advanced Pancreatic Cancer (APC) Receiving Chemotherapy (poster presentation). Updated Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Advanced Pancreatic Cancer (APC) Receiving Chemotherapy (poster presentation). Orlando, FL, US.
- 2019. Optimal Timing for Removal of an Upper Extremity Central Catheter When Associated with a Deep Vein Thrombosis: A Venous Thromboembolism Network US Multicenter Retrospective Cohort Study. Optimal Timing for Removal of an Upper Extremity Central Catheter When Associated with a Deep Vein Thrombosis: A Venous Thromboembolism Network US Multicenter Retrospective Cohort Study. Orlando, FL, US.
- 2018. Risk of Venous Thromboembolism with Abemaciclib and Other CDK4/6 Inhibitors-Based Regimens vs Hormonal Manipulation Regimens in Patients with Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer. Risk of Venous Thromboembolism with Abemaciclib and Other CDK4/6 Inhibitors-Based Regimens vs Hormonal Manipulation Regimens in Patients with Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer. San Antonio, TX, US.
- 2018. Clinical Features of Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia: A Series of 14 Cases. Clinical Features of Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia: A Series of 14 Cases. San Diego, CA, US.
- 2018. Wide Variation in Duration of Anticoagulation after Catheter-Related Thrombosis: A Venous Thromboembolism Network US Multicenter Retrospective Cohort Study. Wide Variation in Duration of Anticoagulation after Catheter-Related Thrombosis: A Venous Thromboembolism Network US Multicenter Retrospective Cohort Study. San Diego, CA, US.
- 2017. Incidence of Venous Thromboembolism in Patients with Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Treated with CDK 4/6 Inhibitors: A Systematic Review and Meta- Analysis of Randomized Controlled Trials (poster presentation). Incidence of Venous Thromboembolism in Patients with Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Treated with CDK 4/6 Inhibitors: A Systematic Review and Meta- Analysis of Randomized Controlled Trials (poster presentation). San Antonio, TX, US.
- 2016. Low- Molecular Weight Heparins (LMWH) Versus Vitamin K Antagonists (VKAs) in the Treatment and Secondary Prevention of Cancer-Associated Venous Thromboembolism (VTE): A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs) [Oral Presentation]. Low- Molecular Weight Heparins (LMWH) Versus Vitamin K Antagonists (VKAs) in the Treatment and Secondary Prevention of Cancer-Associated Venous Thromboembolism (VTE): A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs) [Oral Presentation]. San Diego, CA, US.
- 2016. Risk of Bleeding from Primary Thromboprophylaxis (PTP) in Patients with Solid Cancer Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCT)[Poster Presentation]. Risk of Bleeding from Primary Thromboprophylaxis (PTP) in Patients with Solid Cancer Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCT)[Poster Presentation]. San Diego, CA, US.
- 2016. A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCT) in Ambulatory Thromboprophylaxis (ATP) in Patients with Lung Cancer Receiving Chemotherapy [Poster Presentation]. A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCT) in Ambulatory Thromboprophylaxis (ATP) in Patients with Lung Cancer Receiving Chemotherapy [Poster Presentation]. San Diego, CA, US.
- 2016. Update on the Prevention and Treatment of Venous Thromboembolism in Acute inpatient Cancer Rehabilitation Units. Update on the Prevention and Treatment of Venous Thromboembolism in Acute inpatient Cancer Rehabilitation Units. Chicago, IL, US.
- 2016. Performance of 4T Score and HIT Antibody in the Diagnosis of Heparin-Induced Thrombocytopenia (HIT) in Cancer Patients [Poster Presentation]. Performance of 4T Score and HIT Antibody in the Diagnosis of Heparin-Induced Thrombocytopenia (HIT) in Cancer Patients [Poster Presentation]. Las Vegas, AZ, US.
- 2016. Hematology Education Project. Hematology Education Project. Lakeland, FL, US.
- 2016. Primary Thromboprophylaxis in Ambulatory Patients with Lung Cancer Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [Poster Presentation]. Primary Thromboprophylaxis in Ambulatory Patients with Lung Cancer Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [Poster Presentation]. Hollywood, FL, US.
- 2014. Mortality from Cancer-Associated Venous Thromboembolism in Cancer Patients. Mortality from Cancer-Associated Venous Thromboembolism in Cancer Patients. San Francisco, CA, US.
- 2014. Efficacy of Therapeutic Dose Versus Prophylactic Dose of Anticoagulants in the Primary Prevention of Thrombotic Events in Ambulatory Patients with Solid Malignancies Receiving Chemotherapy: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. Efficacy of Therapeutic Dose Versus Prophylactic Dose of Anticoagulants in the Primary Prevention of Thrombotic Events in Ambulatory Patients with Solid Malignancies Receiving Chemotherapy: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. San Francisco, CA, US.
- 2014. Benefit and Risk of Primary Thromboprophylaxis in Ambulatory Patients with Advanced Pancreatic Cancer Receiving Chemotherapy: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. Benefit and Risk of Primary Thromboprophylaxis in Ambulatory Patients with Advanced Pancreatic Cancer Receiving Chemotherapy: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. San Francisco, CA, US.
- 2014. Incidence and Management of Hematologic Toxicities Associated with Treatment of Hepatitis C virus Infection in Cancer Patients. Incidence and Management of Hematologic Toxicities Associated with Treatment of Hepatitis C virus Infection in Cancer Patients. San Francisco, CA, US.
- 2013. Prevention and Treatment of Venous Thromboembolism in Cancer Patients. Prevention and Treatment of Venous Thromboembolism in Cancer Patients. New York, NY, US.
- 2012. Bleeding Risk in Thrombocytopenic Cancer Patients with Venous Thromboembolism Receiving Anticoagulation. Bleeding Risk in Thrombocytopenic Cancer Patients with Venous Thromboembolism Receiving Anticoagulation. Atlanta, GA, US.
- 2012. Essentials of Preparation for a Residency Program. Essentials of Preparation for a Residency Program. Staten Island, NY, US.
- 2012. Prevention of Venous Thromboembolism in Cancer. International Symposium on Supportive Care in Cancer. New York, NY, US.
- 2010. A Rare Cause of Stroke. A Rare Cause of Stroke. Boston, MA, US.
- 2008. How to join US Postgraduate Residency Programs as Burmese Medical Graduates. How to join US Postgraduate Residency Programs as Burmese Medical Graduates. Chicago, IL, US.
- 2008. Anemia, Leukopenia, and Thrombocytopenia: What Do I Do Next?. Anemia, Leukopenia, and Thrombocytopenia: What Do I Do Next?. New York, NY, US.
- 2007. How to join US Residency as Burmese Medical Graduates. How to join US Residency as Burmese Medical Graduates. New York, NY, US.
- 2007. Strategies in Hematology: Thrombocytopenia, Leukocytopenia and Anemia: What Do I Do Next?. Strategies in Hematology: Thrombocytopenia, Leukocytopenia and Anemia: What Do I Do Next?. Boston, MA, US.
- 2007. Strategies in Hematology: Thrombocytopenia, Leukopenia and Anemia: What Do I Do Next?. Strategies in Hematology: Thrombocytopenia, Leukopenia and Anemia: What Do I Do Next?. Boston, MA, US.
- 2004. Emerging Trends in Antiemetic Therapy. Emerging Trends in Antiemetic Therapy. Kansas City, KS, US.
- 2004. Current Trends in Antiemetic Therapy. Current Trends in Antiemetic Therapy. Columbia, MO, US.
- 2004. Current Trends in Antiemetic Therapy - Round Table Discussion. Current Trends in Antiemetic Therapy - Round Table Discussion. Springfield, MO, US.
- 2004. Both EGF-Like Modules of Plasmodium Falciparum MSP-1 Are Crucial for Interaction with the Erythrocyte Receptor Band-3. Both EGF-Like Modules of Plasmodium Falciparum MSP-1 Are Crucial for Interaction with the Erythrocyte Receptor Band-3. Miami, FL, US.
- 2003. Plasmodium Falciparum Invasion of Erythrocytes Requires Direct Interaction Between Parasite Ligand ABRA and Host Band-3 Receptor. Plasmodium Falciparum Invasion of Erythrocytes Requires Direct Interaction Between Parasite Ligand ABRA and Host Band-3 Receptor. San Diego, CA, US.
- 2003. Emerging Trends in Antiemetic Therapy in 21st Century. Emerging Trends in Antiemetic Therapy in 21st Century. Orlando, FL, US.
- 2003. Interaction of Erythrocyte Band-3 with Two Domains of Merozoite Surface Protein-9 Detected by the Yeast Two-Hybrid Screening of a Plasmodium Falciparum cDNA Library. Interaction of Erythrocyte Band-3 with Two Domains of Merozoite Surface Protein-9 Detected by the Yeast Two-Hybrid Screening of a Plasmodium Falciparum cDNA Library. Woodshole, MA, US.
- 2003. Plasmodium Falciparum Merozoite Surface Protein 1 and 9 Form a Co-Ligand Complex Binding to the Erythrocyte Receptor Band-3. Plasmodium Falciparum Merozoite Surface Protein 1 and 9 Form a Co-Ligand Complex Binding to the Erythrocyte Receptor Band-3. Philadelphia, PA, US.
- 2002. Mapping of the Band 3 Binding Regions in Plasmodium Facipparum Merozoite Surface Protein-1 (MSP-1). Mapping of the Band 3 Binding Regions in Plasmodium Facipparum Merozoite Surface Protein-1 (MSP-1). Woodshole, MA, US.
- 2000. STI 571 Inhibition of BCR/ABL Transformed Cells, is Potentiated by Hyperthermia (poster presentation). STI 571 Inhibition of BCR/ABL Transformed Cells, is Potentiated by Hyperthermia (poster presentation). San Francisco, CA, US.
International Presentations
- 2024. Primary ambulatory thromboprophylaxis (PATP) in patients with lung cancer undergoing systemic therapy: Updated analysis of randomized studies. Poster. European Hematology Association. Madrid, ES.
- 2024. Hyperhomocystinemia-associated thrombosis in patients with pernicious anemia. Poster. British Society for Haematology. Liverpool, GB.
- 2023. A Systematic Review and Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophyaxis (PATP) in Patients with Lymphoma Receiving Chemotherapy. Poster. European Hematology Association. Frankfurt, DE.
- 2023. Diagnostic difficulties in pernicious anemia (Webinar). Invited. Diagnostic difficulties in pernicious anemia. Yangon (Rangoon), MM.
- 2022. Approach to Bleeding Disorders (Webinar). Invited. Approach to Bleeding Disorders (Webinar). Rangoon, MM.
- 2022. Cyclin-Dependent Kinase 4/6 Inhibitors-Associated Venous Thromboembolism in Patients with Hormone Receptor-Positive Breast Cancer. Poster. European Society of Medical Oncology (ESMO) Annual Meeting. Paris, FR.
- 2022. Approach to anemia, leukopenia and thrombocytopenia (Webinar). Approach to anemia, leukopenia and thrombocytopenia (Webinar). Rangoon, MM.
- 2021. Antithrombotic Therapy and Interpretation of D-Dimer (Webinar). Antithrombotic Therapy and Interpretation of D-Dimer (Webinar). Rangoon, MM.
- 2021. Thromboprophylaxis in Covid-19 (Webinar). Thromboprophylaxis in Covid-19 (Webinar). Rangoon, MM.
- 2021. Approach to Bleeding Disorders (Webinar). Approach to Bleeding Disorders (Webinar). Mandalay, MM.
- 2020. A Systematic Review and Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Ovarian Cancer Receiving Chemotherapy (Virtual Web Presentation). Poster. A Systematic Review and Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Ovarian Cancer Receiving Chemotherapy (Virtual Web Presentation). Birmingham, GB.
- 2020. Approach to Bleeding Disorders (Webinar). Invited. Approach to Bleeding Disorders. Rangoon, MM.
- 2019. Prevention and Treatment of Venous Thromboembolism in inpatient rehabilitation units. Invited. Myanmar Society of Rehabilitation Medicine. Yangon, MM.
- 2019. Recent Advances in the Prevention and Treatment of Venous Thromboembolism. Invited. Recent Advances in the Prevention and Treatment of Venous Thromboembolism. Yangon, MM.
- 2019. Thrombotic Microangiopathies. Invited. Myanmar Society of Haematology. Yangon, MM.
- 2019. Immune Thrombocytopenia - Revisited. Invited. International Society of Thrombosis & Haemostasis - Myanmar Society of Haematology. Yangon, MM.
- 2019. Catheter Related Thrombosis in Patients with Hematologic Malignancies: a VENUS Multicenter Retrospective Cohort Study (poster presentation). Poster. International Society of Thrombosis and Haemostasis. Melbourne, AU.
- 2019. Natural History of Heparin-Induced Thrombocytopenia (HIT) in Cancer: A Cohort Analysis of Thrombosis and Bleeding Outcomes (poster presentation). Poster. Annual Meeting of the International Society of Thrombosis and Haemostasis. Melbourne, AU.
- 2019. Approach to Bleeding Disorders. Visiting. Melaka, MY.
- 2019. Update on Cancer Associated Thrombosis. Visiting. Melaka, MY.
- 2019. Common Bleeding Disorders in Cancer Patients. Invited. Rangoon, MM.
- 2019. Update on Cancer Associated Thrombosis. Invited. Rangoon, MM.
- 2019. Postgraduate Medical Education in the United States and Canada. Invited. Rangoon, MM.
- 2019. Common Bleeding Disorders in Cancer Patients. Invited. Rangoon, MM.
- 2018. Updated Meta-Analysis of Randomized Controlled Trials (RCTs) to Determine the CDK 4/6 Inhibitors Associated Venous Thromboembolism (VTE) Risk in Hormone Receptor-Positive Breast Cancer (BC) Patients (poster presentation). Poster. European Society of Medical Oncology (ESMO). Munich, DE.
- 2018. Updates on Cancer Associated Thrombosis. Invited. Rangoon, MM.
- 2018. What's new with new oral anticoagulants?. Invited. Rangoon, MM.
- 2018. Cancer Associated Thrombosis. Invited. Rangoon.
- 2018. Postgraduate Medical Training in North America. Invited. Rangoon.
- 2018. What's new with new oral anticoagulants?. Invited. Rangoon.
- 2018. Common Bleeding Disorders in Cancer Patients. Invited. Annual Meeting of the Multinational Association for Supportive Care in Cancer. Vienna, AT.
- 2017. Postgraduate Medical Training in UK and USA: My experience as a foreign medical graduate. Invited. Yangon, MM.
- 2017. Thrombosis in Endocrine Disorders. Invited. Thrombosis in Endocrine Disorders. Yangon, MM.
- 2017. Thrombosis in Endocrine Disorders. Biannual Meeting of the ASEAN Federation of Endocrine Societies. Yangon, MM.
- 2017. Approach to Thrombotic Microangiopathies. Invited. Yangon, MM.
- 2017. Cancer Associated Thrombosis. Invited. Rangoon.
- 2017. Cancer Associated Thrombosis. Invited. Rangoon.
- 2017. Therapeutic Apheresis. Invited. Rangoon.
- 2017. Cancer Associated Thrombosis. Invited. Rangoon.
- 2017. Approach to Thrombotic Microangiopathies. Invited. Biannual Meeting of the Myanmar Society of Hematology. Rangoon.
- 2017. Direct Anticoagulants. Myanmar Society of Hematology. Rangoon.
- 2017. Anemia, Leucopenia and Thrombocytopenia: What do I do next?. Invited. Rangoon.
- 2017. When Cancer Patients Are HIT: A Literature Review of Heparin-Induced Thrombocytopenia (HIT) and Clinical Outcomes in Cancer Patients. Invited. International Society of Thrombosis and Haemostasis. Berlin, DE.
- 2017. Venous Thromboembolism in Acute Leukemia: Improved Survival with Anticoagulation. Conference. Annual Meeting of the ISTH. Berlin, DE.
- 2017. Approach to Bleeding Disorders. Invited. Rangoon.
- 2017. Approach to Bleeding Disorders. Invited. Rangoon.
- 2017. Cancer Associated Thrombosis. Invited. Rangoon.
- 2016. Clinical Approach to Bleeding Disorders. Invited. Rangoon.
- 2016. Clinical Approach to Bleeding Disorders. Invited. Rangoon.
- 2016. Approach to Bleeding Disorders. Invited. Rangoon.
- 2015. Tumor Board. Tumor Board of Pinlon Hospital. Rangoon.
- 2015. Round the Table Case Discussion. Round the Table Case Discussion. Rangoon.
- 2015. Basics of Hemostasis & Thrombosis. Invited. Rangoon.
- 2015. Round the Table Case Discussion on Thrombosis. Round the Table Case Discussion on Thrombosis. Rangoon, MM.
- 2015. Cancer Associated Thrombosis. Cancer Associated Thrombosis. Rangoon, MM.
- 2015. Approach to Bleeding Disorders. Approach to Bleeding Disorders. Rangoon, MM.
- 2015. Approach to Anemia, Leukopenia, Thrombocytopenia. Approach to Anema, Leukopenia, Thrombocytopenia. Rangoon, MM.
- 2013. Approach to Bleeding Disorders. Approach to Bleeding Disorders. Rangoon, MM.
- 2013. New Anticoagulants in the Prevention and Treatment of Venous Thromboembolism. New Anticoagulants in the Prevention and Treatment of Venous Thromboembolism. Rangoon, MM.
- 2013. Anemia, Leukopenia and Thrombocytopenia: What do I do next?. Anemia, Leukopenia and Thrombocytopenia: What do I do next?. Rangoon, MM.
- 2013. Approach to Bleeding Disorders. Approach to Bleeding Disorders. Rangoon, MM.
- 2013. Presentation of Cases and Discussions. Presentation of Cases and Discussions. Rangoon, MM.
- 2013. Round the Table Case Discussions. Round the Table Case Discussions. Rangoon, MM.
- 2013. Round the Table Case Discussions. Round the Table Case Discussions. Mandalay, MM.
- 2013. Anemia, Leukopenia and Thrombocytopenia: What do I do next?. Anemia, Leukopenia and Thrombocytopenia: What do I do next?. Mandalay, MM.
- 2013. Approach to Bleeding Disorders and Bleeding Emergencies. Approach to Bleeding Disorders and Bleeding Emergencies. Magway, MM.
- 2013. Principles of Management of Acute Leukemias. Principles of Management of Acute Leukemias. Magway, MM.
- 2013. Review of Blood and Bone Marrow Smears - Practical Session. Review of Blood and Bone Marrow Smears - Practical Session. Magway, MM.
- 2013. Approach to Bleeding Disorders and Bleeding Emergencies. Approach to Bleeding Disorders and Bleeding Emergencies. Rangoon, MM.
- 2013. Hematologic Emergencies in the Intensive Care Unit. Hematologic Emergencies in the Intensive Care Unit. Rangoon, MM.
- 2013. Anemia, Leukopenia, Thrombocytopenia: What do I do next?. Anemia, Leukopenia, Thrombocytopenia: What do I do next?. Rangoon, MM.
- 2013. Hematologic Emergencies in the Intensive Care Unit. Hematologic Emergencies in the Intensive Care Unit. Rangoon.
- 2013. Principles of Management of Acute Leukemias. Principles of Management of Acute Leukemias. Rangoon, MM.
- 2013. Review of Blood and Bone Marrow Smears - Practical Session. Review of Blood and Bone Marrow Smears - Practical Session. Rangoon, MM.
- 2013. Approach to Bleeding Disorders and Bleeding Emergencies. Approach to Bleeding Disorders and Bleeding Emergencies. Rangoon, MM.
- 2013. Principles of Management of Acute Leukemias. Principles of Management of Acute Leukemias. Rangoon.
- 2013. Hematologic Emergencies in the Intensive Care Unit. Hematologic Emergencies in the Intensive Care Unit. Rangoon, MM.
- 2013. How to join US Residency Training Programs as Burmese Medical Graduates. How to join US Residency Training Programs as Burmese Medical Graduates. Rangoon, MM.
- 2012. Prevention of Venous Thromboembolism in Cancer. Prevention of Venous Thromboembolism in Cancer. New York, US.
Patient Reviews
CV information above last modified March 31, 2025